Current peptide HIV type-1 fusion inhibitors

Antiviral Chemistry and Chemotherapy

Volumn 20, Issue 1, 2009, Pages 1-18

  Pang, Wei ^a   Tom, Siu Cheung ^b   Zheng, Yong Tang ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b Chinese University of Hong Kong   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL CYSTYLCYSTYLGLYCINE GLYCOPROTEIN GP 41; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CHIMERIC PROTEIN; CP 32M; CP 621 652; CYCLOPEPTIDE; DP 107; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HR 121; HR 212; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HYBRID PROTEIN; IQN 17; IZN 17; MEMBRANE ANCHORED PEPTIDE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PEPTIDE CP 32M; PEPTIDE CP 621 652; PEPTIDE DERIVATIVE; PEPTIDE DP 107; PEPTIDE HR 121; PEPTIDE HR 212; PEPTIDE IQN 17; PEPTIDE IZN 17; PEPTIDE SC 34; PEPTIDE SJ 2176; PEPTIDE T 2410; PEPTIDE T 2635; PROTEIN DERIVATIVE; RECOMBINANT PROTEIN; SC 34; SIFUVIRTIDE; SJ 2176; SYNTHETIC PEPTIDE; T 2410; T 2635; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRIP POLYPEPTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VIRUS ENTRY;

DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HUMANS; PEPTIDE FRAGMENTS;

EID: 70350345494     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1369     Document Type: Review

References (93)

1. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871.
2. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224:500-503.
3. UNAIDS. Report on the global AIDS epidemic: XVII International AIDS Conference. Mexico City, Mexico, 3-8 August 2008. UNAIDS/08.27E/ JC1511E. (English original, July 2008).
4. Nahman, C. HIV drug information database. (Updated 9 September 2008. Accessed 10 January 2009.) Available from http://www.coreynahman.com/ antiHIVdrugdatabase61499.html
5. Harling G, Wood R, Beck EJ. Efficiency of Intervention in HIV Infection, 1994-2004. Disease Management and Health Outcomes 2005; 13:371-394.
6. Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2006; 3:e4.
7. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009; 33:307-320.
8. Wilson LE, Gallant JE. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clin Infect Dis 2009; 48:214-221.
9. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93:681-684.
10. Dimitrov DS. Cell biology of virus entry. Cell 2000; 101:697-702.
11. Jones PL, Korte T, Blumenthal R. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem 1998; 273:404-409.
12. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280:1884-1888.
13. Jiang S, Lin K, Strick N, et al. HIV-1 inhibition by a peptide. Nature 1993; 365:113.
14. Jiang S, Lin K, Strick N, et al. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem Biophys Res Commun 1993; 195:533-538.
15. Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994; 91:9770-9774.
16. Esté JA, Telenti A. HIV entry inhibitors. Lancet 2007; 370:81-88.
17. Zhang X, Lalezari JP, Badley AD, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004; 75:558-568.
18. Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol 2004; 44:793-803.
19. Freed EO, Martin MA. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem 1995; 270:23883-23886.
20. Dong XN, Xiao Y, Dierich MP, et al. N- and C-domains of HIV-1 gp41: mutation, structure and functions. Immunol Lett 2001; 75:215-220.
21. Aloia RC, Jensen FC, Curtain CC, et al. Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci U S A 1988; 85:900-904.
22. Gordon CA, Hodges NA, Marriott C. Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa. J Antimicrob Chemother 1988; 22:667-674.
23. Gallaher WR, Ball JM, Garry RF, et al. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989; 5:431-440.
24. Schaal H, Klein M, Gehrmann P, et al. Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion. J Virol 1995; 69:3308-3314.
25. Delahunty MD, Rhee I, Freed EO, et al. Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues. Virology 1996; 218:94-102.
26. Freed EO, Delwart EL, Buchschacher GL, Jr., et al. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A 1992; 89:70-74.
27. Pritsker M, Rucker J, Hoffman TL, et al. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes. Biochemistry 1999; 38:11359-11371.
28. Owens RJ, Tanner CC, Mulligan MJ, et al. Oligopeptide inhibitors of HIV-induced syncytium formation. AIDS Res Hum Retroviruses 1990; 6:1289-1296.
29. + lymphocytes. Biochim Biophys Acta 1992; 1139:251-256.
30. Charloteaux B, Lorin A, Crowet JM, et al. The N-terminal 12 residue long peptide of HIV gp41 is the minimal peptide sufficient to induce significant T-cell-like membrane destabilization in vitro. J Mol Biol 2006; 359:597-609.
31. Chambers P, Pringle CR, Easton AJ. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol 1990; 71:3075-3080.
32. Cao J, Bergeron L, Helseth E, et al. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol 1993; 67:2747-2755.
33. Chen SS, Lee CN, Lee WR, et al. Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J Virol 1993; 67:3615-3619.
34. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2:1075-1082.
35. Malashkevich VN, Chan DC, Chutkowski CT, et al. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci U S A 1998; 95:9134-9139.
36. Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
37. Weissenhorn W, Dessen A, Harrison SC, et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387:426-430.
38. Tan K, Liu J, Wang J, et al. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 1997; 94:12303-12308.
39. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 1998; 95:15613-15617.
40. Furuta RA, Wild CT, Weng Y, et al. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998; 5:276-279.
41. Wild C, Oas T, McDanal C, et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 1992; 89:10537-10541.
42. Pereira FB, Goni FM, Muga A, et al. Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: dose and sequence effects. Biophys J 1997; 73:1977-1986.
43. Slepushkin VA, Andreev SM, Sidorova MV, et al. Investigation of human immunodeficiency virus fusion peptides. Analysis of interrelations between their structure and function. AIDS Res Hum Retroviruses 1992; 8:9-18.
44. Slepushkin VA, Kornilaeva GV, Andreev SM, et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein. Virology 1993; 194:294-301.
45. Kliger Y, Aharoni A, Rapaport D, et al. Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell fusion. Structure-function study. J Biol Chem 1997; 272:13496-13505.
46. Gerber D, Pritsker M, Gunther-Ausborn S, et al. Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a dl-amino acid-containing fusion peptide: possible recognition of the fusion complex. J Biol Chem 2004; 279:48224-48230.
47. Münch J, Ständker L, Adermann K, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007; 129:263-275.
48. He Y, Cheng J, Li J, et al. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J Virol 2008; 82:6349-6358.
49. Liu S, Jing W, Cheung B, et al. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem 2007; 282:9612-9620.
50. Gallo SA, Sackett K, Rawat SS, et al. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol 2004; 340:9-14.
51. Armand-Ugón M, Gutiérrez A, Clotet B, et al. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res 2003; 59:137-142.
52. Kliger Y, Gallo SA, Peisajovich SG, et al. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem 2001; 276:1391-1397.
53. Liu S, Lu H, Niu J, et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005; 280:11259-11273.
54. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003; 348:2228-2238.
55. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006; 57:619-627.
56. Wild C, Greenwell T, Shugars D, et al. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses 1995; 11:323-325.
57. Wexler-Cohen Y, Johnson BT, Puri A, et al. Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem 2006; 281:9005-9010.
58. Champagne K, Shishido A, Root MJ. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem 2009; 284:3619-3627.
59. He Y, Cheng J, Lu H, et al. Potent HIV fusion inhibitors against enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci U S A 2008; 105:16332-16337.
60. Baldwin CE, Sanders RW, Deng Y, et al. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004; 78:12428-12437.
61. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004; 54:333-340.
62. Menzo S, Castagna A, Monachetti A, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004; 48:3253-3259.
63. Otaka A, Nakamura M, Nameki D, et al. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl 2002; 41:2937-2940.
64. He Y, Xiao Y, Song H, et al. Design and evaluation of sifuvirtide: a novel HIV-1 fusion inhibitor. J Biol Chem 2008; 283:11126-11134.
65. Wang RR, Yang LM, Wang YH, et al. Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem Biophys Res Commun 2009; 382:540-544.
66. Wang RR. The anti-HIV effects and mechanism of sifuvirtide and extracts from the medicinal plant Rhus Chinensis. [PhD thesis]. Beijing, China: Chinese Academy of Sciences; 2007.
67. Franquelim HG, Loura LM, Santos NC, et al. Sifuvirtide screens rigid membrane surfaces. establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides. J Am Chem Soc 2008; 130:6215-6223.
68. Dai SJ, Dou GF, Qiang XH, et al. Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin 2005; 26:1274-1280.
69. Dwyer JJ, Wilson KL, Davison DK, et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A 2007; 104:12772-12777.
70. Eckert DM, Malashkevich VN, Hong LH, et al. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999; 99:103-115.
71. Eckert DM, Kim PS. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A 2001; 98:11187-11192.
72. Bianchi E, Finotto M, Ingallinella P, et al. Covalent stabilization of coiled-coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A 2005; 102:12903-12908.
73. Bewley CA, Louis JM, Ghirlando R, et al. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 2002; 277:14238-14245.
74. Gustchina E, Louis JM, Bewley CA, et al. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41. J Mol Biol 2006; 364:283-289.
75. Louis JM, Bewley CA, Clore GM. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 2001; 276:29485-29489.
76. Luftig MA, Mattu M, Di Giovine P, et al. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol 2006; 13:740-747.
77. Louis JM, Nesheiwat I, Chang L, et al. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 2003; 278:20278-20285.
78. Ni L, Gao GF, Tien P. Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics. Biochem Biophys Res Commun 2005; 332:831-836.
79. Pang W, Wang RR, Yang LM, et al. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro. Virology 2008; 377:80-87.
80. Hildinger M, Dittmar MT, Schult-Dietrich P, et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 2001; 75:3038-3042.
81. Egelhofer M, Brandenburg G, Martinius H, et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004; 78:568-575.
82. Lohrengel S, Hermann F, Hagmann I, et al. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 2005; 79:10237-10246.
83. de Rosny E, Vassell R, Wingfield PT, et al. Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein. J Virol 2001; 75:8859-8863.
84. Jiang S, Lin K, Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1998; 72:10213-10217.
85. Moore JP, Parren PWHI, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 2001; 75:5721-5729.
86. Golding H, Zaitseva M, de Rosny E, et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 2002; 76:6780-6790.
87. Miller MD, Geleziunas R, Bianchi E, et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 2005; 102:14759-14764.
88. Welch BD, VanDemark AP, Heroux A, et al. Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A 2007; 104:16828-16833.
89. Gallo SA, Wang W, Rawat SS, et al. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 2006; 281:18787-18792.
90. Sun ZY, Oh KJ, Kim M, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008; 28:52-63.
91. Sugaya M, Hartley O, Root MJ, et al. C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells. J Invest Dermatol 2007; 127:1436-1443.
92. Coutant J, Yu H, Clément MJ, et al. Both lipid environment and pH are critical for determining physiological solution structure of 3-D-conserved epitopes of the HIV-1 gp41-MPER peptide P1. FASEB J 2008; 22:4338-4351.
93. Rao S, Hu S, McHugh L, et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci U S A 2005; 102:11993-11998.